Abstract
Aspergillus funiculosus NCIM 1029 has been reported for the production of kojic acid exhibiting antibacterial, antifungal and larvicidal activity against 3rd instar larvae of Aedes aegypti.
Aim of the Study: To check the antifeedant, acute toxicity and sublethal growth effects of fungal metabolite, kojic acid against the agriculture pest, Spodoptera litura.
Materials and Methods: Kojic acid was checked for feeding deterrence activity against 4th instar larvae of S. litura in comparison to insect antifeedant, azadirachtin. Reduction in the weight and length of the larvae was evaluated after three days of exposure to kojic acid (400μg/ml). The effect of kojic acid on pupation and adult emergence was also studied.
Results: On determination of feeding deterrence, the DC50 value for kojic acid was found to be 180.645 ± 6.35μg/ml on comparison to azadirachtin (DC50 = 41.372 ± 2.21). The LD50 & LD90 values of kojic acid were found to be 693.52± 51.31 and 1889.13 ± 279.03μg/ml, respectively. The reduction in larval weight and length were 83.24 and 87.50%, respectively. The percentage pupation and adult emergence were reduced by 69% and 64% for the exposed larvae.
Conclusions: Kojic acid showed moderate feeding deterrence, acute toxicity and sublethal growth effects against S. litura.
Keywords: Aspergillus funiculosus, kojic acid, Spodoptera litura, acute toxicity, antifeedant.
The Natural Products Journal
Title:Feeding Deterrence, Acute Toxicity and Sublethal Growth Effects of Kojic Acid Isolated from Aspergillus funiculosus
Volume: 4 Issue: 1
Author(s): Siddhardha Busi, Jobina Rajkumari and Sairengpuii Hnamte
Affiliation:
Keywords: Aspergillus funiculosus, kojic acid, Spodoptera litura, acute toxicity, antifeedant.
Abstract: Aspergillus funiculosus NCIM 1029 has been reported for the production of kojic acid exhibiting antibacterial, antifungal and larvicidal activity against 3rd instar larvae of Aedes aegypti.
Aim of the Study: To check the antifeedant, acute toxicity and sublethal growth effects of fungal metabolite, kojic acid against the agriculture pest, Spodoptera litura.
Materials and Methods: Kojic acid was checked for feeding deterrence activity against 4th instar larvae of S. litura in comparison to insect antifeedant, azadirachtin. Reduction in the weight and length of the larvae was evaluated after three days of exposure to kojic acid (400μg/ml). The effect of kojic acid on pupation and adult emergence was also studied.
Results: On determination of feeding deterrence, the DC50 value for kojic acid was found to be 180.645 ± 6.35μg/ml on comparison to azadirachtin (DC50 = 41.372 ± 2.21). The LD50 & LD90 values of kojic acid were found to be 693.52± 51.31 and 1889.13 ± 279.03μg/ml, respectively. The reduction in larval weight and length were 83.24 and 87.50%, respectively. The percentage pupation and adult emergence were reduced by 69% and 64% for the exposed larvae.
Conclusions: Kojic acid showed moderate feeding deterrence, acute toxicity and sublethal growth effects against S. litura.
Export Options
About this article
Cite this article as:
Busi Siddhardha, Rajkumari Jobina and Hnamte Sairengpuii, Feeding Deterrence, Acute Toxicity and Sublethal Growth Effects of Kojic Acid Isolated from Aspergillus funiculosus, The Natural Products Journal 2014; 4 (1) . https://dx.doi.org/10.2174/2210315504666140515004643
DOI https://dx.doi.org/10.2174/2210315504666140515004643 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Approaches to Novel Anti-Alzheimer Therapy
Current Pharmaceutical Design Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Retina Repair, Stem Cells and Beyond
Current Neurovascular Research Future Targets in Endometriosis Treatment: Targeting the Endometriotic Implant
Mini-Reviews in Medicinal Chemistry Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Molecular Mechanisms of PPAR-γ Governing MSC Osteogenic and Adipogenic Differentiation
Current Stem Cell Research & Therapy Selenium and Clinical Trials: New Therapeutic Evidence for Multiple Diseases
Current Medicinal Chemistry Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD+ Precursor Nicotinamide
Current Medicinal Chemistry Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Life Under Stress: The Probiotic Stress Response and How it may be Manipulated
Current Pharmaceutical Design Herb-Drug Interactions in Neurological Disorders: A Critical Appraisal
Current Drug Metabolism Dietary Fiber Gap and Host Gut Microbiota
Protein & Peptide Letters Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design Lentiviral Vector-Based Models of Amyloid Pathology: From Cells to Animals
Current Alzheimer Research TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Current Pharmaceutical Design